Ra Medical Systems (RMED) Environmental, Social & Governance (ESG) Data

Company Profile

Search within these filings

View filings

Exhibits within filings

Filing insights

Export filings list

Export a CSV file of filings or unique filing companies (up to first 5,000 results).

Download list of filings Download list of companies

Employees

Data from SEC filings

Employee count

ESG framework mentions

In last year of SEC filings

Sustainability Accounting Standards Board (SASB)

No mentions

Global Reporting Initiative (GRI)

No mentions

Task Force on Climate-related Financial Disclosures (TCFD)

No mentions

UN Sustainable Development Goals (SDGs)

No mentions

ESG term mentions

In last year of SEC filings

Clean Climate Environment Environmental Environmental Protection Extreme Weather Materials Natural Gas Nature Offset Packaging Pandemic Plastic Raw Materials Waste Water Access Benefits Black California Consumer Privacy Act Charitable Community Culture Customer Cyber Cyber Security Cybersecurity Data Security Death Disability Diversity Employee Employee Retention Employee Training Engagement Gender Health and Safety Health Care Healthcare Hire Hiring Human Resources Incident Injuries Injury Minority Perquisites Privacy Product Quality Product Safety Recall Recruit Recruitment Reimbursement Retention Retirement Safety Satisfaction Skill Skilled Skills Social Society Stakeholder Supplier Supply Chain Talent Training Union Workforce Anti-corruption Assessment Assurance Attorney General Attorneys General Audit Bonus Bribery Chronic Class Action Lawsuit Classified Classified Board Commitment Conflict of Interest Corporate Governance Corporate Purpose Corruption Department of Ethics Executive Compensation Expert Fined Fraud Goals Governance Hedging Incentive Independence Independent Innovate Innovation Innovative Investigation Lawsuit Lead Independent Director Leadership Litigation Long-term Majority Oversee Oversight Perquisite Plaintiff Proxy Access Proxy Contest Purpose Quality Standard R&D Reputation Reputational Research and Development Responsibility Responsible Special Meeting Strategy Sustainable Targets Tax Tenure Transparency Voting Rights

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM

On March 21, 2023, the Company held a Special Meeting at which, of the 2,492,558 shares of the Company’s common stock outstanding as of February 3, 2023, the record date for the Special Meeting, 1,304,967 shares of common stock were represented, either in person or by proxy, constituting, of the shares entitled to vote, approximately 52.35% of the outstanding shares of common stock.
At the Special Meeting, the Company’s stockholders considered five proposals, which are described in more detail in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on February 9, 2023. The matters voted on at the Special Meeting and the votes cast with respect to each such matter are set forth below.

Proposal No. 1: Approval of, in Accordance with NYSE American Company Guide Section 713(a), the Issuance of More than 19.99% of the Company’s Outstanding Common Stock. In accordance with NYSE American Company Guide Section 713(a), the issuance of more than 19.99% of our outstanding common stock, par value $0.0001 per share upon the exercise of our Series E Common Stock Purchase Warrants, with the right for such potential exercise to occur immediately, was approved based on the following results of voting:

Votes For		Votes Against		Abstentions		Broker Non-Votes

259,937		77,670		7,238		960,122

Proposal No. 2: Approval of, in Accordance with NYSE American Company Guide Section 713(a), the Issuance of More than 19.99% of the Company’s Outstanding Common Stock. In accordance with NYSE American Company Guide Section 713(a), the issuance of more than 19.99% of our outstanding Common Stock (a) in connection with our sale of Class A units, which contain shares of common stock and Series F and G Common Stock Purchase Warrants, and Class B units, which contain shares of Series A Convertible Preferred Stock and Series F and G Common Stock Purchase Warrants, and (b) upon the exercise of the Series F and G Common Stock Purchase Warrants and the conversion of Series A Convertible Preferred Stock, with the right for such potential exercise or conversion to occur immediately, was approved based on the following results of voting:

Votes For		Votes Against		Abstentions		Broker Non-Votes

262,554		75,678		6,613		960,122

Proposal No. 3: Approval, in Accordance with NYSE American Company Guide Section 712(b), the Issuance of Shares of Company Common Stock upon Conversion of Outstanding Series X Preferred Stock. In accordance with NYSE American Company Guide Section 712(b), the issuance of the Common Stock upon conversion of the Company’s Series X Convertible Preferred Stock, par value $0.0001 per share, which shares of Series X Convertible Preferred Stock were issued upon the closing of the merger between the Company and Catheter Precision, Inc., was approved based on the following results of voting:

Votes For		Votes Against		Abstentions		Broker Non-Votes

268,043		70,714		6,088		960,122

Proposal No. 4: Ratification of Auditors. The appointment of Haskell & White LLP as the Company’s independent registered public accounting firm for the fiscal year ended December 31, 2022 was ratified based on the following results of voting:

Votes For		Votes Against		Abstentions		Broker Non-Votes

1,248,217		29,547		27,203		0

Proposal No. 5: Approval of the Adjournment of the Special Meeting. The approval of the adjournment of the Special Meeting, if necessary, to continue to solicit votes for Proposal Nos. 1, 2, 3 and 4 was approved based on the following results of voting, although no such adjournment was required as a result of Proposal Nos. 1, 2, 3 and 4 being approved:

Votes For		Votes Against		Abstentions		Broker Non-Votes

1,181,196		87,075		36,696		0